Tocilizumab
From Wikipedia, the free encyclopedia
Tocilizumab?
|
|
Therapeutic monoclonal antibody | |
Source | Humanized |
Target | ? |
Identifiers | |
CAS number | ? |
ATC code | L04 |
PubChem | ? |
Chemical data | |
Formula | ? |
Mol. mass | ? |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Tocilizumab (under development by Roche and Chugai under the trade name Actemra) is a humanized monoclonal antibody against interleukin-6 used as an immunosuppressive drug.
As of 2008, it is currently under regulatory review by the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA).
|